Meyer Colin John's Form 4 filing
Reata Pharmaceuticals Inc (RETA) · filed May 17, 2023
- Accession no.
- 0001209191-23-030211
- Filed
- May 17, 2023
- Trade date
- May 15-16, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $527.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meyer Colin JohnCIK 0001662392 | Officer (Chief Innovation Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2023 | Class A common stock | SSaleDisposed | −4,469 | $84.76 | −$378,792.44 | 80,137 | Direct | |
| May 15, 2023 | Class A common stock | SSaleDisposed | −1,139 | $85.77 | −$97,692.03 | 78,998 | Direct | |
| May 16, 2023 | Class A common stock | SSaleDisposed | −625 | $80.94 | −$50,587.5 | 78,373 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.